All news from Anaesthesiology

Patients with High-Risk RCC do not Benefit from Lymphadenectomy

In an ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial, researchers compared two different kinase inhibitors used in the setting with a placebo control arm. The trial sought to find whether removing any suspicious lymph nodes at the time of the nephrectomy might improve results. The team aimed at to wipe out any remaining micrometastatic disease and the results of the analysis are published in the Journal of Urology.